SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5301)1/2/2002 7:05:22 PM
From: Elmer  Respond to of 52153
 
Peter,
I posted this to the Maxygen thread during the middle of last year on Festo. Do you think the interpretation is correct and if so, who will win and lose?
Message 16128360



To: Biomaven who wrote (5301)1/2/2002 7:30:56 PM
From: Elmer  Read Replies (1) | Respond to of 52153
 
In my previous post, I said "who will win and lose?" I didn't mean the case. I meant, if the decision is upheld, which biotech companies (if any) will win and which will lose.

It would seem the protein based drug companies would be at risk such as Amgen and HGSI. Maxygen and Diversa might be winners because their gene shuffling technology could slightly alter proteins of existing drugs into new patentable drugs.
Regards,
David


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News